UNSPSC 51282534: Ceftezole sodium

This classification denotes a cephalosporin antibiotic with the molecular formula C13H11N8O4S3.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3NHZ4Y117H, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 8-oxo-7-((1h-tetrazol-1-ylacetyl)amino)-3-((1,3,4-thiadiazol-2-ylthio)methyl)-, monosodium salt, (6r-trans)- but more generally known as ceftezole sodium, which bears US NIH Compound Identifier 170470.

UNSPSC 51282534 Ceftezole sodium is a Commodity code that nominally designates a specific antibiotic pharmaceutical product, but recent state and local procurement activity under this code shows limited direct sourcing for ceftezole itself. Instead, the posted opportunities reflect broader pharmaceutical supply and emergency-response procurement where state and local agencies acquire pharmaceuticals and related medical supplies through piggybacked master agreements or standalone competitive bidding. The work involves pharmaceutical warehousing, distribution, and supply contracts that state agencies and counties use to stock inventory for public health and emergency response programs, with pricing typically fixed and delivery structured on a scheduled or as-needed basis.

Illinois Department of Public Health and Seminole County, Florida represent the recent issuing bodies active under this code, reflecting state health department and county-level procurement participation. The Illinois Department of Public Health awarded a completed piggyback pharmaceutical warehouse contract through MMCAP Infuse to Chartwell Rx LLC in August 2026 for Doxycycline Hyclate and Ciprofloxacin Hydrochloride with a three-year total value of $2,999,999.11, while Seminole County released an IFB in June 2026 to procure 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The geographic footprint spans at least Florida and Illinois, with neither jurisdiction reporting specific set-asides or disadvantaged-enterprise preferences on these procurements. Activity under this code appears sparse relative to the breadth of pharmaceutical sourcing state and local agencies conduct; the mismatch between the code's nominal focus on ceftezole and the actual pharmaceutical products solicited suggests this code may not be the primary vehicle for this type of procurement.